Objective: We aimed to assess the relative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate (MTX) compared to placebo plus MTX in active rheumatoid arthritis (RA).
INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovial joint inflammation, which leads to disability and loss of quality of life. 1, 2 Tumor necrosis factor-a (TNF-a) is a potent pro-inflammatory cytokine that plays an important role in inflammatory and immune responses, including those involved in RA. 3 Thus, TNF-a is an important target of anti-RA therapy. TNF antagonists, especially when administered with methotrexate (MTX), are among the most effective therapies for RA.
Infliximab, a monoclonal antibody specific for TNFa, in combination with MTX has shown significant clinical efficacy versus placebo plus MTX in the treatment of RA. 4 However, the extreme cost is a barrier to widespread use and poses a significant economic burden to the patient and healthcare system. Moreover, infliximab has reached patent expiration, which has enabled the development of biosimilar-infliximab. The biosimilar version is similar to an already licensed reference biologic in terms of quality, safety and efficacy, 5 and its reduced cost has the potential to increase access to this therapy. However, because biosimilars are supported by less clinical research than the reference biologics, there are only limited data about its usage.
Because of the growing availability of biosimilars, it is important to combine the available data and to provide objective quantitative estimates of the efficacy and safety of biosimilars. Several clinical trials have attempted to evaluate the efficacy and safety of biosimilar + MTX versus infliximab + MTX and infliximab + MTX versus placebo + MTX in patients with active RA who have experienced an incomplete response to MTX. [6] [7] [8] [9] [10] [11] [12] However, to our knowledge, no previous studies have directly compared biosimilar + MTX and placebo + MTX. Network meta-analyses enable an assessment of the comparative effectiveness of multiple interventions and combine evidence across a network of randomized controlled trials (RCTs), even in the absence of head-to-head comparisons. 13 A network meta-analysis that includes not only the trials comparing the biosimilar with the originator, but also the studies comparing the originator with the previous standard of care, is warranted to increase the clinical evidence supporting biosimilars. This study aimed to assess the relative efficacy and safety of biosimilar-and originator-infliximab in combination with MTX compared to placebo + MTX in patients with active RA using a network meta-analysis.
METHODS

Identification of eligible studies and data extraction
We conducted an exhaustive search for studies that investigated the efficacy and safety of biosimilarinfliximab + MTX, infliximab + MTX, and/or placebo + MTX in patients with active RA who showed an inadequate response to MTX. A literature search was performed using MEDLINE, EMBASE and the Cochrane library to identify available articles published up to February 2018. The following key words and subject terms were used in the search: 'infliximab' and 'rheumatoid arthritis'. All references in the studies were reviewed to identify additional studies not included in the electronic databases. RCTs were included if they met the following criteria: (i) the study compared biosimilar (3 mg/kg) + MTX with infliximab (3 mg/ kg) + MTX or infliximab (3 mg/kg) + MTX with placebo + MTX in the treatment of patients with active RA who had an incomplete response to MTX; (ii) the study provided endpoints for the clinical efficacy and safety of biosimilar/infliximab/placebo + MTX in the treatment of RA for ≥ 22 weeks; and (iii) the study included patients diagnosed with RA based on either the American College of Rheumatology (ACR) criteria for RA 14 or the 2010 ACR/EULAR (European League Against Rheumatism) classification criteria. 15 The exclusion criteria were: (i) the study included duplicate data; (ii) the study included infliximab or biosimilar with a higher dose than 3 mg/kg; and (iii) the study did not contain adequate data for inclusion. The primary endpoint for efficacy was the number of patients who achieved an ACR 20% (ACR20) response rate, whereas the safety outcome was the number of patients who had experienced serious adverse events (SAEs). The secondary endpoint for efficacy was the number of patients who achieved ACR 50% (ACR50) or ACR 70% (ACR70) response rates. The data were extracted from original studies by two independent reviewers. Any discrepancy between the reviewers was resolved by consensus. The following information was extracted from each publication: the first author, year of publication, number of patients treated with biosimilar/infliximab/ placebo + MTX, length of follow-up, and outcomes in terms of efficacy and tolerability. We quantified the methodological qualities of the seven studies using Jadad scores. 16 The Jadad scale assesses random assignment, double-blinding, and patient withdrawal and dropout rates, with scores ranging from 0 to 5. Study quality was classified as high (score of 3-5) or low (score of 0-2). We conducted a network meta-analysis in accordance with the guidelines provided by the Preferred Reporting Items for Systematic reviews and MetaAnalyses statement. 17 
Evaluation of statistical associations for network meta-analysis
The efficacy and safety of biosimilar + MTX, infliximab + MTX, and placebo + MTX in the treatment of RA were arranged in the order of the probability of being ranked as the best performing agent. We performed a Bayesian random-effects network metaanalysis using NetMetaXL 18 and WinBUGS statistical analysis program version 1.4.3 (MRC Biostatistics Unit, Institute of Public Health, Cambridge, UK). The Bayesian meta-analysis approach offers greater flexibility for the use of more complex models and different outcome types, thereby enabling the simultaneous comparison of all treatment options. We chose a random-effects model for the network meta-analysis, because it incorporates between-study variations and utilizes a conservative method. The random network model was selected prior to the statistical analysis. We used the Markov chain Monte Carlo method to obtain pooled effect sizes. 13 All chains were run with 10 000 burn-in iterations followed by 10 000 monitoring iterations. Information on relative effects was converted to a probability that a treatment is the best, second best and so on, by ranking each treatment according to the surface under the cumulative ranking curve (SUCRA). 19 The SUCRA value is 1 when a treatment is certain to be the best, and 0 when a treatment is certain to be the worst. SUCRA values enable the overall ranking of treatments for a particular outcome. SUCRA simplifies the information on the effect of each treatment into a single number, thereby assisting the decision-making process. The league table arranges the presentation of summary estimates by ranking the treatments in the order of the most pronounced effect on the outcome under consideration, based on the SUCRA value. 19 We reported the pairwise odds ratio (OR) and 95% credible interval (CrI) (or Bayesian confidence interval) and adjusted for multiple-arm trials. Pooled results were considered statistically significant if the 95% CrI did not contain the value 1.
Subgroup analysis, sensitivity analysis and inconsistency assessment
We performed a subgroup analysis according to the follow-up period. A sensitivity test was performed by comparing the random-and fixed-effects models. Inconsistency refers to the extent of disagreement between direct and indirect evidence 20 and this assessment of inconsistency is important when conducting a network meta-analysis, because 21 an inconsistency plot provides information that can help identify the loops in which the inconsistency resides. 21 We plotted the posterior mean deviance of the individual data points in the inconsistency model against the posterior mean deviance in the consistency model to assess the network inconsistency between direct and indirect estimates in each loop. 22 
RESULTS
Studies included in the meta-analysis
A total of 1252 studies were identified through electronic searches, and 13 studies were selected for a fulltext review based on the title and abstract details (Supporting Information). However, six of the 13 studies were excluded, because of duplication 6, 23 (n = 2), MTX-na€ ıve patients 24, 25 (n = 2), no data on ACR response data 26 (n = 1) and short follow-up period 27 (n = 1) (Supporting Information). A study by Abe et al. 27 was excluded, because the follow-up period of RCT was too short to be included in this meta-analysis and the study by Maini et al. 26 was not included, because the study did not provide data on ACR response as the efficacy outcome. Thus, seven RCTs that included 2606 patients (1316 events for efficacy and 262 events for safety) met the inclusion criteria [6] [7] [8] [9] [10] [11] [12] ( Table 1 ). All the RCTs provided data on efficacy and safety. The evidence network diagram shows data related to the number of studies that compared different treatments and the number of patients included in each treatment (Fig. 1, Table 1 ). There were three pairwise comparisons and three types of interventions, including three studies of biosimilar + MTX, seven of infliximab + MTX and four of placebo + MTX in the network meta-analysis (Table 1, Fig. 1 ). The subjects received an intravenous infusion of biosimilar-infliximab (3 mg/kg), originator-infliximab (3 mg/kg), or placebo at weeks 0, 2 and 6, and then every 8 weeks, on a background of MTX. The Jadad scores of the studies ranged 3-4, indicating a high quality of studies ( Table 1 ). The follow-up period of infliximab + MTX was 52 weeks, but the follow-up period of placebo + MTX was 28 weeks in the study by Schiff et al. 10 We used the data on 28 weeks of follow-up period of placebo + MTX, because there were no data on 52 weeks of follow-up period of placebo + MTX. Relevant features of the studies included in the metaanalysis are provided in Table 1 .
Network meta-analysis of the efficacy of biosimilar + MTX, infliximab + MTX and MTX in RCTs Biosimilar + MTX is listed in the top left of the diagonal of the league table (Table 2) because it was associated with the most favorable SUCRA for the ACR20 response rate, whereas placebo + MTX (MTX group) is listed in the bottom right of the diagonal of the league table because it was associated with the least favorable results. For interpretation purposes, the results are read from top to bottom and left to right. The ACR20 response rate was significantly higher in the biosimilar + MTX group than in the MTX group (OR 3.31, 95% CrI 1.74-6.06) ( Table 2 , Fig. 2) . Similarly, the ACR20 response rate was significantly higher in the infliximab + MTX group than in the MTX group (OR 3.15, 95% CrI 1.99-4.70) ( Table 2 , Fig. 2 ). However, there was no difference in the ACR20 response rate between the biosimilar + MTX and infliximab + MTX groups (Table 2, Fig. 2 ). Ranking probability based on SUCRA indicated that biosimilar + MTX had the highest probability of being the best treatment in terms of the ACR20 response rate (SUCRA = 0.7964), followed by infliximab + MTX (SUCRA = 0.7018), and MTX (SUCRA = 0.0018) ( Table 3 ). The ACR50 and ACR70 response rates showed a similar distribution pattern to the ACR20 response rate (Supporting Information). Regarding the safety outcomes, we considered the number of patients who had experienced SAEs. Although the difference was not statistically significant, this number tended to be lower in the placebo + MTX group than in both the biosimilar + MTX and infliximab + MTX groups (Tables 2 and 3 , Fig. 2 ). Ranking probability based on SUCRA values indicated that placebo + MTX had the highest probability of being the safest treatment, followed by infliximab + MTX and biosimilar + MTX (Table 3) . However, there was no significant difference between SUCRA values of infliximab + MTX and biosimilar + MTX (Table 3) .
Subgroup analysis, sensitivity analysis and inconsistency assessment
We performed a subgroup analysis to compare the efficacy and safety at a follow-up period of 54 weeks, as two studies had a shorter follow-up period than 54 weeks. 10, 11 However, subgroup analysis excluding the two studies with a follow-up period less than 54 weeks did not meaningfully change the network Figure 2 Bayesian network meta-analysis results of randomized controlled studies on the relative efficacy based on the number of patients who achieved an ACR20 response rate (a) and safety based on the number of patients who had experienced SAEs (b) of biosimilar + MTX, infliximab + MTX, and placebo + MTX. ACR20, American College of Rheumatology 20% response; SAEs, significant adverse events; MTX, methotrexate. meta-analysis results. In addition, the random-and fixed-effects model results provided the same interpretation, indicating that the results of this network metaanalysis were robust (Fig. 2) . Inconsistency plots assessing network inconsistencies between direct and indirect estimates showed a low possibility for inconsistencies that might significantly affect the results of the network meta-analysis (Fig. 3) .
DISCUSSION
We conducted a network meta-analysis to compare the relative efficacy and safety of biosimilar + MTX and infliximab + MTX compared to placebo + MTX in patients with active RA unresponsive to MTX treatment. This analysis approach was chosen because it allows for an indirect comparison of multiple treatments that are either lacking in or have insufficient direct head-to-head comparisons. 13 We evaluated biosimilar-and originator-infliximab in combination with MTX instead of monotherapy because they are commonly used in combination with MTX. MTX inhibits the activation and proliferation of lymphocytes; thus, the combination of biosimilar-and originator-infliximab with MTX leads to a pharmacological synergism that augments the mode of action of these two drugs. 28 Our network meta-analysis assessed the number of patients who achieved ACR20, 50 and 70 responses and the number of them who experienced SAEs in the three differently treated, active RA patient groups. We then generated a rank order of efficacy and safety of the three treatment paradigms for patients with active RA. Our network metaanalysis suggests that biosimilar + MTX has the highest efficacy in the treatment of active RA, followed by infliximab + MTX and then MTX alone. Statistically significant differences between the MTX group and both the biosimilar + MTX and infliximab + MTX groups were observed with respect to the primary endpoint (ACR20 response) and secondary endpoints (ACR50 and ACR70 response rate). However, no statistically significant difference in the ACR response rates was found between biosimilar-infliximab and originator-infliximab. With respect to safety based on the number of SAEs, biosimilar + MTX and infliximab + MTX caused more SAEs and had a lower probability of being optimal in terms of SAEs compared to placebo + MTX. However, no significant difference in the number of SAEs was observed among the three interventions, which suggests comparable safety between them.
In this study, we used a network meta-analysis technique 29 that combines all direct and indirect evidence to estimate the treatment effects of all treatments of interest; biosimilar-infliximab had only been previously compared to infliximab in a head-to-head RCT, infliximab had only been compared to placebo, and head-tohead comparisons between biosimilar and placebo were nonexistent. The clinical consequences generated by our network meta-analysis should be considered as a reinforcement of the available clinical evidence on the use of biosimilar-infliximab, as it incorporated all comparisons of available data into a single analysis and may in fact provide 'total evidence'. Our results should be interpreted with caution owing to the following shortcomings of the study. First, the follow-up time points ranged widely, that is, from 22 weeks to 54 weeks. Therefore, the follow-up duration was heterogeneous and relatively short for an evaluation of treatment effects. Hence, future longer comparative studies with a homogeneous follow-up duration are warranted. Second, the design and patient characteristics of the analyzed studies were heterogeneous, and these inter-study differences may have affected the results of our network meta-analysis. Third, our study did not comprehensively address the efficacy and safety outcomes of biosimilar-infliximab and originator-infliximab in RA. We focused solely on the treatment efficacy based on the number of patients who achieved ACR20, 50 or 70 responses, and on the safety according to the number of SAEs, without assessing various other outcomes. Specifically, the number of SAEs may not be sufficient as a safety outcome measure because of its frequency.
In conclusion, using a Bayesian network meta-analysis involving seven RCTs that compared three different interventions, we found that biosimilar-infliximab and originator-infliximab, in combination with MTX, represented an efficacious intervention for active RA that did not carry a significant risk of SAEs. However, no statistically significant difference in efficacy and safety was found between biosimilar-and originator-infliximab. Long-term studies are needed to determine the relative efficacy and safety of biosimilar-and originator-infliximab in a large number of patients with active RA.
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